New insights on the pathomechanisms of inflammatory bowel disease

Journal of Digestive Diseases

Volumn 14, Issue 9, 2013, Pages 455-462

  Abdullah, Murdani ^a   Syam, Ari Fahrial ^a   Simadibrata, Marcellus ^a   Gunawan, Jeffri ^a   Makmun, Dadang ^a   Rani, Abdul Aziz ^a  

^a UNIVERSITY OF INDONESIA   (Indonesia)

Author keywords

Inflammatory bowel disease; Limited pathway; Microbiome; New immune cell populations; Pathomechanism

Indexed keywords

CRYOPYRIN; GUANINE NUCLEOTIDE BINDING PROTEIN; INTERFERON REGULATORY FACTOR 5; INTERLEUKIN 10; INTERLEUKIN 23 RECEPTOR; INTERLEUKIN 27; JANUS KINASE 2; LYMPHOCYTESPECIFIC PROTEIN 1; M PROTEIN; NON RECEPTOR PROTEIN TYROSINE PHOSPHATASE 2; UNCLASSIFIED DRUG;

ADAPTIVE IMMUNITY; BACTERIAL INFECTION; CELL DIFFERENTIATION; CHLAMYDIA TRACHOMATIS; CYTOMEGALOVIRUS; ENDOPLASMIC RETICULUM STRESS; ENTERITIS; ENVIRONMENTAL FACTOR; ESCHERICHIA COLI; GENETIC RISK; GENETIC VARIABILITY; HUMAN; IMMUNOCOMPETENT CELL; INCIDENCE; INFLAMMATION; INNATE IMMUNITY; INTESTINE FLORA; LISTERIA MONOCYTOGENES; MICROENVIRONMENT; MUCOSAL IMMUNITY; MYCOBACTERIUM PARATUBERCULOSIS; OXIDATIVE STRESS; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; SACCHAROMYCES CEREVISIAE; T LYMPHOCYTE;

INFLAMMATORY BOWEL DISEASE; LIMITED PATHWAY; MICROBIOME; NEW IMMUNE CELL POPULATIONS; PATHOMECHANISM;

ENDOPLASMIC RETICULUM STRESS; GENE-ENVIRONMENT INTERACTION; GENETIC PREDISPOSITION TO DISEASE; HUMANS; IMMUNITY, CELLULAR; INFLAMMATORY BOWEL DISEASES; INTESTINES; MICROBIOTA; SYMBIOSIS;

EID: 84881639643     PISSN: 17512972     EISSN: 17512980     Source Type: Journal    
DOI: 10.1111/1751-2980.12081     Document Type: Review

References (53)

1. Thia KT, Loftus EV Jr, Sandborn WJ, Yang SK. An update on the epidemiology of inflammatory bowel disease in Asia. Am J Gastroenterol 2008; 103: 3167-3182.
2. Leong RW, Lau JY, Sung JJ. The epidemiology and phenotype of Crohn's disease in the Chinese population. Inflamm Bowel Dis 2004; 10: 646-651.
3. Lok KH, Hung HG, Ng CH etal. Epidemiology and clinical characteristics of ulcerative colitis in Chinese population: experience from a single center in Hong Kong. J Gastroenterol Hepatol 2008; 23: 406-410.
4. Jiang L, Xia B, Li J etal. Retrospective survey of 452 patients with inflammatory bowel disease in Wuhan city, Central China. Inflamm Bowel Dis 2006; 12: 212-217.
5. Ng SC, Tang W, Ching J etal. Incidence and phenotype of inflammatory bowel disease based on results from the Asia-Pacific Crohn's and colitis epidemiology study. Gastroenterology 2013; doi: 10.1053/j.gastro.2013.04.007. [Epub ahead of print]
6. Abdullah M, Djojoningrat D, Syam AF etal. Epidemiology and clinical characteristic of IBD in Indonesia: a multi-centre study. In: Fraser A, Gibson PR, Hibi T etal., eds. Falk Symposium 151: Emerging Issues in Inflammatory Bowel Diseases. Sydney: Springer; 2006; 138.
7. Ott SJ, Kühbacher T, Musfeldt M etal. Fungi and inflammatory bowel diseases: alterations of composition and diversity. Scand J Gastroenterol 2008; 43: 831-841.
8. Khor B, Gardet A, Xavier RJ. Genetics and pathogenesis of inflammatory bowel disease. Nature 2011; 474: 307-317.
9. Virgin HW, Todd JA. Metagenomics and personalized medicine. Cell 2011; 147: 44-56.
10. Fiocchi C. IBD: advances in pathogenesis, complications, diagnosis, and therapy. Curr Opin Gastroenterol 2012; 28: 297-300.
11. Lakatos PL, Fischer S, Lakatos L, Gal I, Papp J. Current concept on the pathogenesis of inflammatory bowel disease - crosstalk between genetic and microbial factors: pathogenic bacteria and altered bacterial sensing or changes in mucosal integrity take 'toll'? World J Gastroenterol 2006; 12: 1829-1841.
12. Borody TJ, Warren EF, Leis S, Surace R, Ashman O. Treatment of ulcerative colitis using fecal bacteriotherapy. J Clin Gastroenterol 2003; 37: 42-47.
13. Hotte NS, Salim SY, Tso RH etal. Patients with inflammatory bowel disease exhibit dysregulated responses to microbial DNA. PLoS ONE 2012; 7: e37932.
14. Steck N, Mueller K, Schemann M, Haller D. Bacterial proteases in IBD and IBS. Gut 2012; 61: 1610-1618.
15. Steck N, Hoffmann M, Sava IG etal. Enterococcus faecalis metalloprotease compromises epithelial barrier and contributes to intestinal inflammation. Gastroenterology 2011; 141: 959-971.
16. Scharl M, Rogler G. Inflammatory bowel disease pathogenesis: what is new? Curr Opin Gastroenterol 2012; 28: 301-309.
17. Nunes T, Fiorino G, Danese S, Sans M. Familial aggregation in inflammatory bowel disease: is it genes or environment? World J Gastroenterol 2011; 17: 2715-2722.
18. Franke A, McGovern DP, Barrett JC etal. Genome-wide meta-analysis increases to 71 the number of confirmed Crohn's disease susceptibility loci. Nat Genet 2010; 42: 1118-1125.
19. Anderson CA, Boucher G, Lees CW etal. Meta-analysis identifies 29 additional ulcerative colitis risk loci, increasing the number of confirmed associations to 47. Nat Genet 2011; 43: 246-252.
20. Rivas MA, Beaudoin M, Gardet A etal. Deep resequencing of GWAS loci identifies independent rare variants associated with inflammatory bowel disease. Nat Genet 2011; 43: 1066-1073.
21. Travassos LH, Carneiro LA, Ramjeet M etal. Nod1 and Nod2 direct autophagy by recruiting ATG16L1 to the plasma membrane at the site of bacterial entry. Nat Immunol 2010; 11: 55-62.
22. Cooney R, Baker J, Brain O etal. NOD2 stimulation induces autophagy in dendritic cells influencing bacterial handling and antigen presentation. Nat Med 2010; 16: 90-97.
23. Homer CR, Richmond AL, Rebert NA, Achkar JP, McDonald C. ATG16L1 and NOD2 interact in an autophagy-dependent antibacterial pathway implicated in Crohn's disease pathogenesis. Gastroenterology 2010; 139: 1630-1641.
24. Lamkanfi M, Walle LV, Kanneganti TD. Deregulated inflammasome signaling in disease. Immunol Rev 2011; 243: 163-173.
25. Kim YG, Park JH, Reimer T etal. Viral infection augments Nod1/2 signaling to potentiate lethality associated with secondary bacterial infections. Cell Host Microbe 2011; 9: 496-507.
26. Scharl M, Rogler G. Microbial sensing by the intestinal epithelium in the pathogenesis of inflammatory bowel disease. Int J Inflam 2010; 2010: doi: 10.4061/2010/671258.
27. Lin Z, Hegarty JP, Cappel JA etal. Identification of disease-associated DNA methylation in intestinal tissues from patients with inflammatory bowel disease. Clin Genet 2011; 80: 59-67.
28. Ekbom A, Wakefield AJ, Zack M, Adami HO. Perinatal measles infection and subsequent Crohn's disease. Lancet 1994; 344: 508-510.
29. Ekbom A, Daszak P, Kraaz W, Wakefield AJ. Crohn's disease after in-utero measles virus exposure. Lancet 1996; 348: 515-517.
30. Cadwell K, Patel KK, Maloney NS etal. Virus-plus-susceptibility gene interaction determines Crohn's disease gene Atg16L1 phenotypes in intestine. Cell 2010; 141: 1135-1145.
31. Trojanowska D, Zwolinska-Wcislo M, Tokarczyk M, Kosowski K, Mach T, Budak A. The role of Candida in inflammatory bowel disease. Estimation of transmission of C. albicans fungi in gastrointestinal tract based on genetic affinity between strains. Med Sci Monit 2010; 16: CR451-457.
32. Frank DN, Robertson CE, Hamm CM etal. Disease phenotype and genotype are associated with shifts in intestinal-associated microbiota in inflammatory bowel diseases. Inflamm Bowel Dis 2011; 17: 179-184.
33. Rausch P, Rehman A, Künzel S etal. Colonic mucosa-associated microbiota is influenced by an interaction of Crohn disease and FUT2 (secretor) genotype. Proc Natl Acad Sci U S A 2011; 108: 19030-19035.
34. Sokol H, Seksik P, Furet JP etal. Low counts of Faecalibacterium prausnitzii in colitis microbiota. Inflamm Bowel Dis 2009; 15: 1183-1189.
35. Nishikawa J, Kudo T, Sakata S, Benno Y, Sugiyama T. Diversity of mucosa-associated microbiota in active and inactive ulcerative colitis. Scand J Gastroenterol 2009; 44: 180-186.
36. Kang S, Denman SE, Morrison M etal. Dysbiosis of fecal microbiota in Crohn's disease patients as revealed by a custom phylogenetic microarray. Inflamm Bowel Dis 2010; 16: 2034-2042.
37. Darfeuille-Michaud A, Boudeau J, Bulois P etal. High prevalence of adherent-invasive Escherichia coli associated with ileal mucosa in Crohn's disease. Gastroenterology 2004; 127: 412-421.
38. Joossens M, Huys G, Cnockaert M etal. Dysbiosis of the faecal microbiota in patients with Crohn's disease and their unaffected relatives. Gut 2011; 60: 631-637.
39. Sepehri S, Kotlowski R, Bernstein CN, Krause DO. Microbial diversity of inflamed and noninflamed gut biopsy tissues in inflammatory bowel disease. Inflamm Bowel Dis 2007; 13: 675-683.
40. Manichanh C, Rigottier-Gois L, Bonnaud E etal. Reduced diversity of faecal microbiota in Crohn's disease revealed by a metagenomic approach. Gut 2006; 55: 205-211.
41. Scanlan PD, Shanahan F, O'Mahony C, Marchesi JR. Culture-independent analyses of temporal variation of the dominant fecal microbiota and targeted bacterial subgroups in Crohn's disease. J Clin Microbiol 2006; 44: 3980-3988.
42. Ott SJ, Musfeldt M, Wenderoth DF etal. Reduction in diversity of the colonic mucosa associated bacterial microflora in patients with active inflammatory bowel disease. Gut 2004; 53: 685-693.
43. Costello EK, Lauber CL, Hamady M, Fierer N, Gordon JI, Knight R. Bacterial community variation in human body habitats across space and time. Science 2009; 326: 1694-1697.
44. Muegge BD, Kuczynski J, Knights D etal. Diet drives convergence in gut microbiome functions across mammalian phylogeny and within humans. Science 2011; 332: 970-974.
45. Faith JJ, McNulty NP, Rey FE, Gordon JI. Predicting a human gut microbiota's response to diet in gnotobiotic mice. Science 2011; 333: 101-104.
46. Fritz T, Niederreiter L, Adolph T, Blumberg RS, Kaser A. Crohn's disease: NOD2, autophagy and ER stress converge. Gut 2011; 60: 1580-1588.
47. Martinon F, Chen X, Lee AH, Glimcher LH. TLR activation of the transcription factor XBP1 regulates innate immune responses in macrophages. Nat Immunol 2010; 11: 411-418.
48. McGovern DP, Gardet A, Törkvist L etal. Genome-wide association identifies multiple ulcerative colitis susceptibility loci. Nat Genet 2010; 42: 332-337.
49. Hundorfean G, Neurath MF, Mudter J. Functional relevance of T helper 17 (Th17) cells and the IL-17 cytokine family in inflammatory bowel disease. Inflamm Bowel Dis 2012; 18: 180-186.
50. Abraham C, Cho J. Interleukin-23/Th17 pathways and inflammatory bowel disease. Inflamm Bowel Dis 2009; 15: 1090-1100.
51. Geremia A, Arancibia-Cárcamo CV, Fleming MP etal. IL-23-responsive innate lymphoid cells are increased in inflammatory bowel disease. J Exp Med 2011; 208: 1127-1133.
52. Spits H, Di Santo JP. The expanding family of innate lymphoid cells: regulators and effectors of immunity and tissue remodeling. Nat Immunol 2011; 12: 21-27.
53. Mjösberg JM, Trifari S, Crellin NK etal. Human IL-25- and IL-33-responsive type 2 innate lymphoid cells are defined by expression of CRTH2 and CD161. Nat Immunol 2011; 12: 1055-1062.